Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis

INTRODUCTION: BI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. Phase I and Ic studies were conducted to investigate the safety, tolerability and pharmacokinetics of BI 1015550 in healthy male subjects and patients with idiopathic pulmonary fibrosis (IPF). METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Maher, Toby M., Schlecker, Christina, Luedtke, Doreen, Bossert, Sebastian, Zoz, Donald F., Schultz, Armin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589333/
https://www.ncbi.nlm.nih.gov/pubmed/36299369
http://dx.doi.org/10.1183/23120541.00240-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589333/
https://www.ncbi.nlm.nih.gov/pubmed/36299369
http://dx.doi.org/10.1183/23120541.00240-2022

Ejemplares similares